IL164734A0 - Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof - Google Patents

Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Info

Publication number
IL164734A0
IL164734A0 IL16473404A IL16473404A IL164734A0 IL 164734 A0 IL164734 A0 IL 164734A0 IL 16473404 A IL16473404 A IL 16473404A IL 16473404 A IL16473404 A IL 16473404A IL 164734 A0 IL164734 A0 IL 164734A0
Authority
IL
Israel
Prior art keywords
derivatives
carboxylic acids
sub
site
action
Prior art date
Application number
IL16473404A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL164734A0 publication Critical patent/IL164734A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16473404A 2002-05-14 2004-10-20 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof IL164734A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38064102P 2002-05-14 2002-05-14

Publications (1)

Publication Number Publication Date
IL164734A0 true IL164734A0 (en) 2005-12-18

Family

ID=29549994

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16473404A IL164734A0 (en) 2002-05-14 2004-10-20 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Country Status (16)

Country Link
US (2) US7355047B2 (https=)
EP (1) EP1503759B1 (https=)
JP (1) JP4532263B2 (https=)
KR (1) KR20040107525A (https=)
CN (1) CN1652784A (https=)
AT (1) ATE417613T1 (https=)
AU (1) AU2003229043B2 (https=)
BR (1) BR0309965A (https=)
CA (1) CA2484308A1 (https=)
DE (1) DE60325347D1 (https=)
DK (1) DK1503759T3 (https=)
ES (1) ES2319176T3 (https=)
IL (1) IL164734A0 (https=)
MX (1) MXPA04011156A (https=)
NZ (1) NZ536061A (https=)
WO (1) WO2003097564A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1503759T3 (da) * 2002-05-14 2009-04-14 Univ California Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
RU2006142896A (ru) * 2004-05-06 2008-06-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us) Замещенные енаминоны, их производные и их применение
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101155787B (zh) * 2005-04-11 2010-11-24 弗·哈夫曼-拉罗切有限公司 (3,4-二氢-喹唑啉-2-基)-茚满-1-基-胺
DE602006010540D1 (de) * 2005-05-04 2009-12-31 Hoffmann La Roche (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
ATE475650T1 (de) * 2005-12-05 2010-08-15 Merck Sharp & Dohme Positive allosterische chinolon-m1- rezeptormodulatoren
CA2634113A1 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2645376C (en) * 2006-03-13 2017-06-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
CA2660421A1 (en) * 2006-08-10 2008-02-14 Ferrer Internacional S.A. 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
NZ576036A (en) 2006-10-16 2010-10-29 Bionomics Ltd Naphthyridine containing compounds for treating anxiety disorders
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US8436016B2 (en) * 2008-10-23 2013-05-07 Scott D. Kuduk Fused heterocyclic M1 receptor positive allosteric modulators
SI2408750T1 (sl) 2009-03-20 2015-11-30 Vertex Pharmaceuticals Incorporated Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
WO2010114919A2 (en) * 2009-04-02 2010-10-07 Stc.Unm Metnase and intnase inhibitors and their use in treating cancer
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US9023848B2 (en) 2011-03-02 2015-05-05 Bionomics Limited Small-molecules as therapeutics
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
EP2707367B1 (en) 2011-05-12 2019-10-09 Bionomics Limited Methods for preparing naphthyridines
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
CN107501107A (zh) * 2017-09-26 2017-12-22 兰亚朝 喹诺酮药物的中间体合成方法
CN111269131B (zh) * 2020-03-12 2021-12-28 江苏飞宇医药科技股份有限公司 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
JPS5715760B2 (https=) * 1974-06-11 1982-04-01
US4390541A (en) * 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
DE60018274T2 (de) * 1999-05-06 2005-08-04 Neurogen Corp., Branford Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
DK1503759T3 (da) * 2002-05-14 2009-04-14 Univ California Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf

Also Published As

Publication number Publication date
KR20040107525A (ko) 2004-12-20
WO2003097564A3 (en) 2004-02-26
NZ536061A (en) 2008-09-26
AU2003229043B2 (en) 2008-12-04
US20060178516A1 (en) 2006-08-10
AU2003229043A1 (en) 2003-12-02
EP1503759B1 (en) 2008-12-17
HK1072905A1 (en) 2005-09-16
US7355047B2 (en) 2008-04-08
DK1503759T3 (da) 2009-04-14
EP1503759A2 (en) 2005-02-09
US20080176897A1 (en) 2008-07-24
MXPA04011156A (es) 2005-02-17
EP1503759A4 (en) 2006-02-15
BR0309965A (pt) 2005-03-01
WO2003097564A2 (en) 2003-11-27
JP2005535592A (ja) 2005-11-24
ATE417613T1 (de) 2009-01-15
CA2484308A1 (en) 2003-11-27
ES2319176T3 (es) 2009-05-05
CN1652784A (zh) 2005-08-10
JP4532263B2 (ja) 2010-08-25
DE60325347D1 (de) 2009-01-29

Similar Documents

Publication Publication Date Title
IL164734A0 (en) Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
EP1862457A3 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2000045799A3 (de) Verwendung von substituierten isoxazolcarbonsäuren und derivaten und neue stoffe
ATE370943T1 (de) Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
IL162527A0 (en) Novel fluorene carboxylic acid esters, methods forthe production thereof, and use of the same as pharmaceuticals
NO20072767L (no) Gabapentin prodrug vedvarende frigivelse orale doseringsformer
ATE543873T1 (de) Herstellung von 3-hydroxypropionsäure mittels beta-alanine-pyruvat-aminotrransferase
LU90803I2 (fr) Targretin-bexarotene et ses d-riv-s pharmaceutiquement acceptables
EE200300549A (et) Rasvhapete ravitoime võimendamine
WO2004031374A3 (en) Secondary binding site of dipeptidyl peptidase iv (dp iv)
DK0678087T3 (da) Forbindelser med selektiv aktivitet til retinoid-X-receptorer og metoder til modulering af processer medieret af retinoid-X
WO2003032912A8 (en) Treatment of cns disorders using cns target modulators
UA85711C2 (ru) Замещенные енаминоны, их производные и их применение
AU6689900A (en) 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors
BG104801A (en) Indole-2,3-dione-3-oxime derivatives for therapeutical use
DE60216083D1 (de) (OXOPYRAZOLOi1,5AöPYRIMIDIN-2-YL) ALKYLCARBONSÄUREAMIDE
FI20020593A0 (fi) Menetelmä konjugoidun linolihapon valmistamiseksi
AU2003251681A1 (en) Ghrelin binding nucleic acids
AU2002222550A1 (en) Substituted carboxylic acid derivatives
AU2003220106A1 (en) Novel silane modified carboxylic acid substituted amines and salts thereof
AU2003221495A1 (en) Production of carboxylic acid amides
DE602004003173D1 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
WO2003045917A3 (en) Ccr-3 receptor antagonists vii
HK1055059A2 (en) 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS